Table 3.
Clinical features of patients of MDD (n = 48) according to the specific diagnostic categories.
| N | Alu Median (interquartile range) (ng/ml) | P-value | |
|---|---|---|---|
| Total | 48 | 225.2 (139.8–655.3) | |
| Gender | 0.5548 | ||
| Male | 16 (33.3%) | 205.8 (60.9–935.7) | |
| Female | 32 (66.7%) | 225.2 (157.3–543.6) | |
| Psychosis onset age (y) | 0.1088 | ||
| Up to 16 | 6 (12.5%) | 966.6 (773.1–2,075.7) | |
| 17 to 34 | 9 (18.75%) | 340.2 (206.0–482.7) | |
| 35 or more | 33 (68.75%) | 229.1 (164.1–594.3) | |
| Current age (y) | 0.0931 | ||
| 13 to 34 | 12 (25.0%) | 936.5 (279.2–996.8) | |
| 35 or more | 36 (75.0%) | 251.6 (164.1–611.2) | |
| Duration of psychosis (in weeks) | 0.9195 | ||
| Up to 12 | 7 (14.6%) | 299.6 (107.7–782.4) | |
| 13 to 52 | 18 (37.5%) | 242.5 (147.3–665.5) | |
| 53 or more | 23 (39.6%) | 209.3 (155.0–421.8) | |
| Pharmacological treatment (in weeks) | 0.7453 | ||
| Up to 4 | 37 (77.1%) | 251.6 (137.9–543.6) | |
| 5 or more | 11 (22.9%) | 198.7 (157.0–707.3) | |
| Current treatment | 0.4513 | ||
| AD | 22 (45.8%) | 181.3 (95.8–665.5) | |
| AP+AD | 22 (45.8%) | 242.5 (168.6–418.4) | |
| AP+AD+MS | 4 (8.3%) | 345.7 (180.4–1,710.5) | |
| Family history | 0.3321 | ||
| Yes | 4 (8.3%) | 141.7 (130.5–269.0) | |
| No | 44 (91.7%) | 238.6 (147.8–716.9) |
MDD, major depressive disorder; AP, anti-psychotics; AD, antidepressants; MS, mood stabilizers.
P < 0.05 was considered statistically significant.